MEDA: Zyclara Receives Positive Opinion from the Committee for Human Medicinal Products in the European Union
6/25/2012 10:02:32 AM
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding marketing authorization of Zyclara (treatment of actinic keratoses on large skin areas). The European Commission generally follows the recommendations of the CHMP (EMA) and announces its final decision within three months after the recommendation. Following an approval, the marketing authorization is valid across the European Union.